CSL Behring buys Calimmune for early stem cell, gene therapy boost – FierceBiotech
FierceBiotech |
CSL Behring buys Calimmune for early stem cell, gene therapy boost
FierceBiotech CSL Behring has paid out $91 million upfront for biotech Calimmune and gains a preclinical asset for sickle cell disease and β-thalassemia, adding to its blood disease pipeline. The biotech is working on ex vivo hematopoietic stem cell (HSC) gene … CSL snags a preclinical stem cell therapy in $416M Calimmune buyout, plans to spin out HIV effort CSL Behring to Acquire Biotech Company Calimmune and its Proprietary Stem Cell Gene Therapy Platform CSL spends $114m to buy US cell and gene therapy company |
